first issued 18 August 2022

Presentation on chikungunya a and chikungunya vaccines

The National Integrated Comprehensive Cholera Prevention and Control Plan (2017-2022) outlines Uganda's strategy to reduce cholera cases and mortality by 50% by 2022. The plan focuses on improving access to clean water, sanitation, and hygiene (WASH), strengthening disease surveillance, enhancing ca ... se management, and implementing oral cholera vaccination (OCV) in high-risk areas. It emphasizes multi-sectoral collaboration, involving government agencies, NGOs, and local communities to ensure a sustainable response. Key interventions include community engagement, improved health services, and better outbreak preparedness, aiming for long-term cholera elimination in Uganda. more

Geneva, 22 May 2023 – Gavi, the Vaccine Alliance today published a roadmap* outlining critical actions needed to ensure supply of oral cholera vaccine (OCV) is able to meet growing demand from countries. Released against a backdrop of a recent wave of cholera outbreaks around the world, the roadma ... p forecasts the short-, mid- and long-term outlook for global cholera vaccine supply. Developed in consultation with a range of key Alliance partners, including WHO, UNICEF, the Global Taskforce for Cholera Control (GTFCC), and the Bill and Melinda Gates Foundation (BMGF), it describes how these organizations, manufacturers and countries can work together towards ensuring global OCV supply can support largescale preventive vaccination by 2026. more

CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de ... velopment of next-generation vaccines against COVID-19 variants and we are planning studies to answer critical scientific questions related to the durability of immunity, effectiveness of mixed-vaccine regimens, and vaccine effectiveness in vulnerable populations such as pregnant women. We are also bringing forward our plans to develop vaccines that could protect against multiple COVID-19 variants and other coronavirus specie more